Ameriprise Financial Inc Otonomy, Inc. Transaction History

Ameriprise Financial Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.72 - $2.51 $1,720 - $2,510	-1,000 Reduced 4.42%	21,600 $45,000
Q4 2021 Feb 14, 2022	SELL	$1.69 - $2.31 $18,421 - $25,179	-10,900 Reduced 32.54%	22,600 $47,000
Q3 2021 Nov 15, 2021	SELL	$1.22 - $2.2 $16,836 - $30,360	-13,800 Reduced 29.18%	33,500 $64,000
Q1 2021 May 17, 2021	BUY	$2.49 - $6.23 $23,904 - $59,808	9,600 Added 25.46%	47,300 $121,000
Q4 2020 Feb 12, 2021	BUY	$3.48 - $6.47 $131,196 - $243,919	37,700 New	37,700 $238,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.